Sanofi reports data reinforcing efficacy of RSV candidate

Sanofi’s RSV candidate for infants has demonstrated an efficacy of 79.5% against tract infections and hospitalizations, in an analysis of phase III and phase IIb data combined.
Photo: Benoit Tessier/Reuters/Ritzau Scanpix
Photo: Benoit Tessier/Reuters/Ritzau Scanpix
by marketwire, translated by daniel pedersen

On Wednesday, Sanofi reports a 79.5% efficacy for its respiratory syncytial virus (RSV) treatment candidate in infants with lower respiratory tract infections (LRTI), the company has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading